JPRN-jRCT2031220051进行中（未招募）1 期
A Pharmacodynamics and Safety Study of DSP-9632P in Patients with Levodopa-Induced Dyskinesia in Parkinson's Disease
akamura Hiroki0 个研究点目标入组 20 人开始时间: 2022年5月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 < 80age old（—）
- 性别
- All
入选标准
- •1. Subject whose age is >= 50 and < 80 years at the time of informed consent.
- •2. Subject who is fully informed and understands the objectives, procedures, anticipated drug effects/pharmacological action and risks of the study and who voluntarily provides written consent to participate in the study.
- •3. Subject who has clinically established Parkinson's disease diagnosed by MDS clinical diagnostic criteria for Parkinson's disease (2015).
- •4. Subject who has a response to levodopa at screening in the opinion of the investigator.
- •5. Subject who is confirmed to have dopaminergic denervation with a specific binding ratio in the striatum, obtained by dopamine transporter SPECT (123I-FP-CIT, DAT scan) performed prior to the study or at screening, that is lower than the lower limit of 95% confidence interval of healthy adults.
- •6. Subject who has a Hoehn & Yahr stage =< III in the ON state at screening.
- •7. Subject who has MDS-UPDRS Part IV-1 >= 2 and Part IV-2 >= 2 at screening.
- •8. Subject who is on treatment with levodopa formulation at least 3 times daily at screening.
- •9. Subject who is able to receive 11C-raclopride PET scans (Part A only).
- •10. Subject who has a score of >= 2 in any of questions of UDysRS Part 1B at screening (Part B only).
- •11. Subjects who can wear the glasses-type wearable device and agree to wear it (Part B only).
- •12. Subject who is able to comply with the study requirements, including physical examination, assessments, and reporting symptoms.
- •13. Subject who is willing to practice abstinence or use appropriate contraception as part of the subject's lifestyle from signing informed consent through 30 days after the last dose of study drug.
- •14. Subject who is on treatment with levodopa formulation at least 3 times daily and is treated with levodopa formulation with a fixed dosing regimen for at least 28 days prior to Period 1 (Part A) or prior to admission (Part B).
- •15. Subject who is in the ON state with dyskinesia every day for at least 30 minutes twice or more daily based on the PD home diary during the placebo lead-in period (Part B only).
排除标准
- •1. Subject with a clinically significant history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, hematological, respiratory, or neurologic disease other than Parkinson's disease, determined by the investigator.
- •2. Subject who has a disorder or history of a condition that may interfere with drug metabolism or excretion including clinically significant abnormality of the hepatic or renal systems.
- •3. Subject with a history of epilepsy, convulsions, unexplained syncope or other unexplained loss of consciousness (except a single incident), or head trauma with loss of consciousness lasting more than 5 minutes.
- •4. Subject with a clinically significant abnormal 12-lead ECG or a screening 12-lead ECG for safety assessment that demonstrates any one of the following:
- •Heart rate > 100 bpm or < 50 bpm
- •QRS interval > 120 msec
- •QTcF > 450 msec (male) or > 470 msec (female)
- •PR interval > 200 msec
- •5. Subject with dermatosis or skin abnormality (eg, dermatitis, eczema, or dyschromatosis) at application sites.
- •6. Subject with a history of drug allergy or skin allergy.
- •7. Subject with a known sensitivity to any transdermal patch.
- •8. Subject with a history of drug abuse or narcotic abuse, or a positive urine drug screening at screening.
- •9. Subject who has a positive immunology at screening.
- •10. Subject with any clinically significant abnormal clinical laboratory value (hematology test, serum chemistry test, urinalysis, coagulation test, or lipid test) determined by the investigator at screening.
- •11. Subject with a history of biphasic dyskinesia, myoclonus, or apathy.
- •12. Subject with a current or history of psychiatric illness (eg, schizophrenia, bipolar disorder, depression) based on the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5).
- •13. Subject with Mini-Mental State Examination (MMSE) score of =< 23 at screening.
- •14. Subject who has received surgical therapy related to Parkinson's disease.
- •15. Subject who has previously received levodopa-carbidopa intestinal gel.
- •16. Subject who has previously received DSP-9632P.
- •17. Subject who has participated in any clinical study and received any investigational drug during the 90 days prior to screening visit, or who is currently participating in another clinical trial.
- •18. Subject who has experienced significant blood loss or donated blood (>= 400 mL) during the 90 days prior to screening or donated 200 mL of blood or more during the 30 days prior to screening; has donated blood components during the 14 days prior to screening or intends to donate blood components or blood during the 30 days after the last study visit.
- •19. Subject who is in the opinion of the investigator unsuitable in any other way to participate in this study.
- •20. Subject who has a positive urine drug screening at admission.
- •21. Subject who has consumed caffein or smoked in 2 days prior to the admission or has consumed alcohol in 1 day prior to the admission (Part A only).
- •22. Subject who answers yes to Suicidal Ideation Items 4 or 5 on the C-SSRS at admission.
- •23. Subject who has used dopamine receptor antagonists (antipsychotics, metoclopramide, domperidone) within 14 days prior to Period 1.
- •24. Subject who has used serotonergic 5-HT1A/1B agonists/antagonists (tandospirone, sumatriptan, zolmitriptan, eletriptan, rizatriptan, naratriptan, Yokukansan) during the 14 days prior to Period 1.
- •25. Subject who has used therapeutic agents (monoamine oxidase B [MAO-B] inhibitors,
研究者
相似试验
未知
1 期
Pharmacokinetic study of DSP-1958pediatric solid tumor, pediatric brain tumor, malignamt lymphomaJPRN-jRCT2080223378Sumitomo Dainippon Pharma Co., Ltd.15
已完成
1 期
A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's DiseaseLevodopa-induced DyskinesiaParkinson's DiseaseNCT05435729Sumitomo Pharma Co., Ltd.7
招募中
2 期
A safety, efficacy and pharmacokinetic study of SPJ-101CA as a maintenance therapy for newly diagnosed high risk neuroblastomaC04.557.465.625.600.590.650.550neuroblastomaJPRN-jRCT2031220687Makimoto Atsushi16
进行中（未招募）
不适用
Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group studyTreatment of venous lymphatic insufficiency symptoms related to chronic venous disorders.EUCTR2009-014681-25-EEPIERRE FABRE MEDICAMENT84
进行中（未招募）
不适用
Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group studyTreatment of venous lymphatic insufficiency symptoms related to chronic venous disorders.MedDRA version: 12.1Level: LLTClassification code 10066682Term: Chronic venous insufficiencyEUCTR2009-014681-25-LTPIERRE FABRE MEDICAMENT-IRPF-IDPF84